Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-08-01

Study Completion Date

2029-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.

Participants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.

The goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00168025

Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency

COMPLETED PHASE3

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793

Long COVID Long Coronavirus Disease 2019 (Covid19) Long Covid-19

ACTIVE_NOT_RECRUITING PHASE2

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

NCT00661401

Common Variable Immunodeficiency Agammaglobulinemia

COMPLETED NA

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

NCT00542997

Common Variable Immunodeficiency X-linked Agammaglobulinemia Autosomal Recessive Agammaglobulinemia

COMPLETED PHASE3

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00322556

Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study, initiated by Healing Hope International, is designed to collect real-world data (RWD) from individuals diagnosed with Long COVID who are undergoing clinical care involving intranasal immunoglobulin (IVIG) therapy at international medical tourism sites.

Eligible participants are adults (ages 18-65) with:

Persistent Long COVID symptoms for ≥12 weeks following SARS-CoV-2 infection,

Laboratory-confirmed immunodeficiency (e.g., low IgG/IgA, poor vaccine response, or specific antibody deficiency),

Elevated inflammatory biomarkers (e.g., CRP, cytokines),

No evidence of active infection (bacterial, viral, or fungal),

No comorbid neurological conditions (e.g., multiple sclerosis, Alzheimer's disease),

No current immunosuppressive therapies.

No investigational product will be administered by the study team. All treatments are prescribed and delivered independently by licensed international clinical sites. Healing Hope International operates as the sponsor and data coordinating center. Participants' data will be collected retrospectively and prospectively from site medical records, patient-reported surveys, and third-party laboratory assessments, including genetic testing for RXRA expression (e.g., via qPCR or NGS panels).

The primary data endpoints include:

Changes in immunological biomarkers (IgG/IgA, CRP, cytokine panel),

Clinical course of Long COVID symptoms (fatigue, cognitive impairment, respiratory issues),

Quality of life measures (collected via validated patient-reported outcome instruments).

The study complies with all applicable regulations for data protection and ethical research conduct, including informed consent, HIPAA-compliant data transfer where applicable, and de-identification of personal health information. Ethical approval will be obtained from an Institutional Review Board (IRB), and partner sites may obtain parallel local or national ethics approvals.

This study also seeks to characterize the broader landscape of medical tourism for regenerative therapies by mapping treatment accessibility, safety, and patient reported effectiveness in the context of international care. It does not replace or compete with regulated clinical trials but aims to generate actionable real world insights that can guide future controlled research.

By contributing to the body of evidence around global regenerative practices, this study supports the development of international ethical guidelines, compassionate use frameworks, and collaborative trial infrastructure in complex chronic conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Acute Sequelae of SARS-CoV-2 Infection Long COVID Long COVID Fatigue Long COVID Syndrome COVID 19 Associated Coagulopathy COVID-19 Vaccination

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Long COVID Patients with Immunodeficiency

This group includes adult participants (ages 18-65) with a clinical diagnosis of Long COVID and laboratory-confirmed immunodeficiency (e.g., low IgG, low IgA, or specific antibody deficiency). Participants in this cohort are receiving intranasal immunoglobulin (IVIG) therapy as part of their standard care through international clinical sites. Data will be collected on treatment outcomes, cytokine and CRP profiles, antibody titers, and patient-reported symptoms including fatigue, cognitive function, and quality of life. No treatments are administered by the study team.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65 years
* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)
* Laboratory-confirmed immunodeficiency, including one or more of the following:
* Low serum IgG and/or IgA
* Specific antibody deficiency
* Low pneumonia titers
* Elevated inflammatory markers (e.g., CRP, cytokines)
* No active infections at the time of enrollment (bacterial, viral, or fungal)
* Negative for Lyme disease and NMDAR antibodies
* Willingness to provide informed consent for data collection and use

Exclusion Criteria

* Current or recent active infection (e.g., viral, bacterial, or fungal)
* Use of immunosuppressive therapy within the last 3 months
* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded
* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded
* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded
* Inability to comply with study assessments or procedures

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No